Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer | Zendy

SunYoung Kong | Zendy; ByungHo Nam | Zendy; Keun Seok Lee | Zendy; Youngmee Kwon | Zendy; Eun Sook Lee | Zendy; MoonWoo Seong | Zendy; Do Hoon Lee | Zendy; Jungsil Ro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer

Author(s) -

SunYoung Kong,

ByungHo Nam,

Keun Seok Lee,

Youngmee Kwon,

Eun Sook Lee,

MoonWoo Seong,

Do Hoon Lee,

Jungsil Ro

Publication year - 2006

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2006.067512

Subject(s) - immunohistochemistry , breast cancer , metastatic breast cancer , medicine , cancer , pathology , staining

Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression or amplification of the HER-2/neu (HER2, symbol ERBB2) gene, but each technique requires a high-quality tissue sample, which may not be available. We investigated whether serum concentrations of the HER2 extracellular domain (ECD) can be used as an alternative to tissue HER2 status in metastatic breast cancer, and we defined an optimal decision-level concentration of serum HER2 for prediction of tissue HER2 status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research